325 related articles for article (PubMed ID: 24721544)
1. Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid.
Ulrich M; Pellacani G; Ferrandiz C; Lear JT
Eur J Dermatol; 2014; 24(2):158-67. PubMed ID: 24721544
[TBL] [Abstract][Full Text] [Related]
2. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses.
Ulrich C; Johannsen A; Röwert-Huber J; Ulrich M; Sterry W; Stockfleth E
Eur J Dermatol; 2010; 20(4):482-8. PubMed ID: 20507841
[TBL] [Abstract][Full Text] [Related]
3. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.
Dirschka T; Bierhoff E; Pflugfelder A; Garbe C
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):258-63. PubMed ID: 19709346
[TBL] [Abstract][Full Text] [Related]
4. Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety.
Martin GM; Stockfleth E
J Drugs Dermatol; 2012 May; 11(5):600-8. PubMed ID: 22527428
[TBL] [Abstract][Full Text] [Related]
5. Monitoring treatment of field cancerisation with 3% diclofenac sodium 2.5% hyaluronic acid by reflectance confocal microscopy: a histologic correlation.
Malvehy J; Roldán-Marín R; Iglesias-García P; Díaz A; Puig S
Acta Derm Venereol; 2015 Jan; 95(1):45-50. PubMed ID: 24696069
[TBL] [Abstract][Full Text] [Related]
6. Treatment of actinic keratosis through inhibition of cyclooxygenase-2: Potential mechanism of action of diclofenac sodium 3% in hyaluronic acid 2.5.
Thomas GJ; Herranz P; Cruz SB; Parodi A
Dermatol Ther; 2019 May; 32(3):e12800. PubMed ID: 30523664
[TBL] [Abstract][Full Text] [Related]
7. Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety.
Javor S; Cozzani E; Parodi A
G Ital Dermatol Venereol; 2016 Jun; 151(3):275-80. PubMed ID: 26512929
[TBL] [Abstract][Full Text] [Related]
8. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze).
Nelson C; Rigel D; Smith S; Swanson N; Wolf J
J Drugs Dermatol; 2004; 3(4):401-7. PubMed ID: 15303784
[TBL] [Abstract][Full Text] [Related]
9. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses.
Rivers JK; McLean DI
Arch Dermatol; 1997 Oct; 133(10):1239-42. PubMed ID: 9382562
[TBL] [Abstract][Full Text] [Related]
10. Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index.
Schmitz L; Gupta G; Segert MH; Kost R; Sternberg J; Gambichler T; Stockfleth E; Dirschka T
Skin Pharmacol Physiol; 2018; 31(4):206-211. PubMed ID: 29791916
[TBL] [Abstract][Full Text] [Related]
11. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results.
Stockfleth E; Kerl H; Zwingers T; Willers C
Br J Dermatol; 2011 Nov; 165(5):1101-8. PubMed ID: 21517801
[TBL] [Abstract][Full Text] [Related]
12. [The real face of actinic keratosis: field of cancerisation and squamous cell carcinoma].
Basset-Seguin N
Eur J Dermatol; 2012 Dec; 22 Suppl 1():5-9. PubMed ID: 23269757
[TBL] [Abstract][Full Text] [Related]
13. The importance of treating the field in actinic keratosis.
Stockfleth E
J Eur Acad Dermatol Venereol; 2017 Mar; 31 Suppl 2():8-11. PubMed ID: 28263021
[TBL] [Abstract][Full Text] [Related]
14. Clinical, dermoscopic and immunohistochemical assessment of actinic keratoses and evaluation of the effectiveness of diclofenac therapy with immunohistochemical analysis.
Çayirli M; Köse O; Demiriz M
Arch Dermatol Res; 2013 Jul; 305(5):389-95. PubMed ID: 23397597
[TBL] [Abstract][Full Text] [Related]
15. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents.
Berman B; Cohen DE; Amini S
Cutis; 2012 May; 89(5):241-50. PubMed ID: 22768439
[TBL] [Abstract][Full Text] [Related]
16. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: Commonly used field-directed and lesion-directed therapies.
Berman B; Cohen DE; Amini S
Cutis; 2012 Jun; 89(6):294-301. PubMed ID: 22838095
[TBL] [Abstract][Full Text] [Related]
17. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group.
Pflugfelder A; Welter AK; Leiter U; Weide B; Held L; Eigentler TK; Dirschka T; Stockfleth E; Nashan D; Garbe C;
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):48-53. PubMed ID: 21414035
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
19. Safety of topical interventions for the treatment of actinic keratosis.
Koch EAT; Wessely A; Steeb T; Berking C; Heppt MV
Expert Opin Drug Saf; 2021 Jul; 20(7):801-814. PubMed ID: 33834933
[No Abstract] [Full Text] [Related]
20. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases.
Ulrich C; Hackethal M; Ulrich M; Howorka A; Forschner T; Sterry W; Stockfleth E
Br J Dermatol; 2007 May; 156 Suppl 3():40-2. PubMed ID: 17488405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
